DEA Greenlights Opium Imports for Siegfried USA—Legal Highs Ahead?
Published Date: 1/22/2026
Notice
Summary
Siegfried USA, LLC wants to become an official importer of certain controlled substances, like phenylacetone and raw opium. This affects companies handling these drugs and anyone interested can comment or request a hearing by February 23, 2026. No direct costs are mentioned, but this move could impact drug supply chains and regulations.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Comment and Hearing Deadline
Registered bulk manufacturers and applicants can submit electronic comments or objections about Siegfried USA, LLC's importer application, or file a written request for a hearing, on or before February 23, 2026. Comments must be submitted through https://www.regulations.gov and hearing requests must be sent to the DEA addresses listed in the notice.
Importer Application for Schedule II APIs
Siegfried USA, LLC applied on November 27, 2025 to be registered to import the Schedule II substances phenylacetone (code 8501), opium, raw (code 9600), and poppy straw concentrate (code 9670). The company states it plans to import these substances only to manufacture bulk active pharmaceutical ingredients for distribution to its customers, and the registration will not authorize import of finished dosage forms for commercial sale.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2026-01193, L-Lysine From the People's Republic of China: Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Determination With Final Antidumping Duty Determination
The U.S. government found that Chinese companies making L-lysine, a common animal feed ingredient, are getting unfair financial help from their government. Because of this, the U.S. plans to add extra taxes (countervailing duties) on these imports to keep things fair for American businesses. This decision starts January 22, 2026, and could affect prices and trade between the U.S. and China.
Next: 2026-01195, Notice of Intent To Extend and Revise a Previously Approved Information Collection
The USDA’s National Institute of Food and Agriculture plans to extend and update the Expanded Food and Nutrition Education Program’s data collection for three more years. This affects educators and volunteers teaching nutrition to families with limited money across all 50 states and territories. They’re asking for public comments by March 23, 2026, to help improve how they track and boost the program’s impact.